For weight-loss clinics, a good faith exam before prescribing semaglutide cannot rely on the same intake used for Botox or fillers. A generic form may miss metabolic candidacy, contraindications, concurrent medications, objective baseline data, and the clinical reasoning supporting treatment.
The sections below explain what the evaluation should cover, how it differs from an aesthetic GFE, which risks and health data matter, when telehealth may be appropriate, and what should trigger reassessment. Requirements vary by state, patient location, provider authority, and clinical circumstances.
The Short Answer for Busy Clinics
Quick Answer: Is a good faith exam required for semaglutide? States do not use one uniform term or rule. In general, the prescriber must establish an appropriate patient relationship, complete and document a clinically adequate evaluation, and determine that semaglutide is appropriate before issuing the prescription.
The evaluator must be authorized to assess and prescribe for the patient where the patient is located. Telehealth may be permitted, but the acceptable interaction and required findings vary.
Why a Weight-Loss Drug Rewrites the Exam
Aesthetic and semaglutide evaluations answer different clinical questions.
| Exam element | Aesthetic GFE: Botox or fillers | Semaglutide GFE |
| Clinical focus | Procedure and injection-site suitability | Metabolic diagnosis and treatment candidacy |
| Core screening | Allergies, anticoagulants, prior procedures | Weight history, comorbidities, interactions, and GLP-1 risks |
| Objective data | Usually limited to relevant examination findings | Weight, BMI, vitals, and selected laboratory data |
| Ongoing review | Often tied to a procedure or treatment cycle | Response, tolerability, dose changes, and continuing appropriateness |
An injectable-focused intake may document that a patient can undergo a procedure without establishing why a systemic medication is appropriate. Structured Good Faith Exams for GLP-1 clinics should connect intake, evaluation, prescribing judgment, and follow-up in one traceable record.
Inside the Good Faith Exam Before Prescribing Semaglutide
The provider’s reasoning should be visible in the chart. A defensible good faith exam before prescribing semaglutide typically includes:
- Confirm the patient’s identity and current location for telehealth.
- Record weight history, current weight, BMI, previous interventions, and treatment goals.
- Establish the indication and assess weight-related conditions, including diabetes, hypertension, dyslipidemia, sleep apnea, and cardiovascular disease.
- Review medications, supplements, glucose-lowering therapies, and previous GLP-1 use or intolerance.
- Screen for contraindications, warnings, pregnancy considerations, interactions, and monitoring needs.
- Document the diagnosis, selected product, starting dose, titration, counseling, and follow-up plan.
The note should explain why the treatment and dose fit this patient. The OMA Obesity Algorithm® supports a broader assessment of weight history, complications, secondary contributors, medications, behavior, and long-term management, rather than a BMI-only decision.
Contraindications and Risks That Change the Decision
Formal contraindications should be separated from warnings and monitoring factors. The Ozempic prescribing label 2025 lists a personal or family history of medullary thyroid carcinoma, MEN 2, and prior serious hypersensitivity to semaglutide or its excipients as contraindications.
The prescriber should also screen for and document:
- pregnancy, breastfeeding, or plans for pregnancy;
- pancreatitis history or current concerning symptoms;
- gallstones, cholecystitis, or other gallbladder disease;
- kidney disease and dehydration risk during gastrointestinal illness;
- severe gastroparesis or significant gastrointestinal symptoms;
- type 1 diabetes and concurrent insulin or sulfonylurea use;
- diabetic retinopathy in patients with type 2 diabetes; and
- upcoming procedures involving general anesthesia or deep sedation.
These findings do not all prohibit treatment. They may require different counseling, monitoring, testing, referral, or treatment. The STEP 1 trial, published in the New England Journal of Medicine, can help clinics distinguish the population studied (adults with a BMI ≥30, or ≥27 with a weight-related condition, without diabetes) from patients who need additional assessment.
Labs and Numbers Worth Having on File
Testing should follow the indication, history, medications, symptoms, and prescriber’s judgment.
| Data point | Why it matters |
| Weight, BMI, blood pressure, heart rate | Establishes candidacy and an objective baseline |
| HbA1c or fasting glucose | Identifies dysglycemia and guides diabetes-related decisions |
| Creatinine and eGFR | Supports renal assessment and monitoring during volume depletion |
| Lipid panel | Documents a common weight-related metabolic risk |
| Liver enzymes | Helps assess metabolic liver disease or another relevant condition |
| Pregnancy testing, when indicated | Informs safe prescribing for weight reduction |
| Thyroid evaluation, when indicated | Investigates relevant history, symptoms, or nodules |
Telehealth Good Faith Exam for Semaglutide: When Remote Evaluation Fits
A telehealth good faith exam for semaglutide may support prescribing when the provider is authorized where the patient is located, the modality is permitted, and the encounter can support an adequate evaluation.
| State-dependent issue | What the clinic must determine |
| Provider authority | Whether the provider may practice and prescribe where the patient is located |
| Required interaction | Whether live video, audio-only, or asynchronous review is permitted |
| In-person findings | Whether law or clinical judgment requires an in-person examination |
| Documentation | What identity, location, consent, modality, and findings must be recorded |
A questionnaire-only approval is not automatically sufficient. Missing location checks, unclear licensure, or unavailable findings can weaken the prescribing record. Clinic policy should require the provider to escalate to live video, in-person assessment, additional records, testing, or referral when the available information cannot support a safe decision.
Semaglutide Good Faith Exam Requirements Do Not End at the Prescription
Strong semaglutide good faith exam requirements create a traceable chain from patient information to provider decision. The record should contain:
- patient identity, location, and telehealth consent where applicable;
- provider identity, credentials, and relevant state authority;
- weight history, medical history, medications, vitals, and reviewed results;
- contraindication, warning, and interaction screening;
- examination findings available through the chosen modality;
- assessment, diagnosis, and independent candidacy decision;
- informed-consent discussion, including material risks and alternatives;
- prescribed product, dose, titration, and patient instructions; and
- monitoring, follow-up, escalation, and referral plan.
A later reviewer should not need to reconstruct the prescribing logic from separate systems.
One Exam, or a New One for Every Refill?
There is no universal rule requiring a new formal GFE for every refill. The answer depends on state requirements, treatment changes, the patient’s condition, and clinical judgment. One intake should not function as permanent authorization for indefinite prescribing.
Reassessment becomes especially important when:
- the dose is escalated or restarted after an interruption;
- adverse effects, dehydration, or new risk factors appear;
- weight or metabolic response is inadequate, excessive, or stalled;
- medications, pregnancy status, or relevant conditions change; or
- the patient returns after a material lapse in care.
Who Is Authorized to Perform the Exam?
The professional conducting the GFE before prescribing semaglutide must be authorized to evaluate, diagnose, and prescribe for that patient in that jurisdiction.
- MD or DO: May evaluate and prescribe within licensure, scope, and telehealth rules.
- NP or APRN: May do so when state prescriptive-authority, collaboration, and supervision requirements are met.
- PA: May do so within the state’s delegation, collaboration, supervision, and prescribing framework.
- RN: May collect delegated information but generally cannot replace the prescriber’s diagnosis and treatment decision.
A clinic owner’s title or medical-director agreement does not transfer prescribing authority. Confirm who can perform a Good Faith Exam for the applicable state and service. Clinics should also align staffing, intake, follow-up, and escalation policies with the broader standards for Good Faith Exams for weight loss clinics.
What Skipping the Evaluation Can Cost
Using the same form for all injectables is not enough when that form does not establish semaglutide candidacy. Weak semaglutide GFE compliance can expose the absence of independent medical judgment.
Prescribing without an adequate good faith exam before semaglutide prescription may contribute to:
- a board complaint, record request, investigation, or disciplinary exposure;
- individual license risk for the person who authorized treatment;
- liability allegations if an unassessed risk contributes to harm;
- pharmacy, insurer, credentialing, or payment-processor questions;
- refill disruption when another provider cannot trace the initial decision; and
- reputational harm in a scrutinized treatment category.
The Standard to Hold Your Clinic To: Final Thoughts
The settled principle is that semaglutide prescribing should follow a real, documented clinical evaluation. State terminology, provider authority, telehealth modality, required findings, and reassessment timing may differ.
Audit the clinic’s good faith exam before prescribing semaglutide against five standards: candidacy, risk screening, provider authority, documentation, and follow-up. If the current process was built for aesthetics, identify where it misses metabolic history, label-specific risks, prescribing logic, or ongoing monitoring.
GoodFaithExams.com provides a structured pathway designed to support state-aware evaluations and traceable records for GLP-1 programs. A clinic evaluating this service should compare its current intake, prescriber review, documentation, and reassessment process against the standards above, then correct the gaps before the next prescription.
Frequently Asked Questions
Is a Good Faith Exam required before prescribing semaglutide?
For clinics asking is a good faith exam required for semaglutide, states use different terms and standards. A good faith exam before prescribing semaglutide generally refers to the documented evaluation needed to establish an appropriate patient relationship and support the prescription.
What does a provider assess during a pre-semaglutide Good Faith Exam?
Semaglutide good faith exam requirements should address the indication, weight history, BMI, comorbidities, medications, contraindications, warnings, relevant measurements, and follow-up. The record should show an independent provider decision, not only the patient’s requested treatment.
Who is qualified to prescribe semaglutide and perform the GFE?
An MD, DO, NP, APRN, or PA may qualify if authorized to evaluate and prescribe in the patient’s state. Scope, collaboration, supervision, prescriptive authority, and telehealth rules must be checked for that provider.
Can a semaglutide Good Faith Exam be completed via telehealth?
A telehealth good faith exam for semaglutide may be permitted when the provider is authorized where the patient is located and the modality supports an adequate evaluation. State law or clinical circumstances may require real-time or in-person findings.
What contraindications must a provider identify before semaglutide?
Formal contraindications include a personal or family history of MTC, MEN 2, and prior serious hypersensitivity to semaglutide or its excipients. Other conditions, medications, pregnancy considerations, and label warnings require screening and clinical judgment.
How does a GFE for semaglutide differ from a standard aesthetic GFE?
An aesthetic GFE usually focuses on procedural candidacy and injection-related risks. A semaglutide evaluation addresses metabolic diagnosis, systemic-drug risks, concurrent medications, objective baselines, titration, adverse effects, and continuing treatment appropriateness.
What documentation is required before and after a semaglutide GFE?
For stronger semaglutide GFE compliance, retain identity and location checks, provider credentials, history, findings, reviewed data, risk screening, diagnosis, consent, prescription details, and follow-up. Exact record requirements vary by state and clinical circumstances.
Is a new Good Faith Exam required for each semaglutide prescription refill?
A new good faith exam before semaglutide prescription renewal is not universally required every time. The clinic still needs clinically appropriate reassessment based on state rules, dose changes, response, adverse effects, new conditions, and interruptions in care.
What happens if a clinic prescribes semaglutide without a GFE?
Skipping the GFE before prescribing semaglutide can create board, licensing, liability, pharmacy, payer, and reputational exposure. The degree of risk depends on state law, the record, the prescriber’s conduct, and whether patient harm occurred.
Can a nurse practitioner perform a Good Faith Exam for semaglutide independently?
Sometimes. An NP’s independent authority depends on the patient’s state, the NP’s license and prescriptive authority, and any physician collaboration or supervision requirement. Cross-state telehealth adds separate licensure considerations.
How do state telehealth rules affect semaglutide GFE delivery?
State rules determine provider authorization, patient-location checks, consent, acceptable interaction, prescribing standards, and when an in-person examination is necessary. A model permitted in one state should not be deployed nationwide without state-specific review.
What labs or health data should be reviewed during a semaglutide GFE?
Common data include weight, BMI, blood pressure, heart rate, glucose or HbA1c, and renal function. Lipids, liver enzymes, pregnancy testing, thyroid evaluation, or other tests may be appropriate based on the patient’s history and indication.
